Condition: Recurrent Vulvar Cancer · Persistent Vulvar Cancer · Metastatic Vulva Cancer · Sponsor: AGO Research GmbH
Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.
This description comes directly from the study's public registry record.
Yvonne Treffner, Dr. · +49 201 959812-17 · ytreffner@ago-ovar.de
Office -Essen · +49 201 959812-20 · office-essen@ago-ovar.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Augsburg | Augsburg, Germany | Recruiting |
| Hochtaunus-Kliniken Bad Homburg | Bad Homburg, Germany | Recruiting |
| Universitätsklinikum Carl Gustav Carus Dresden | Dresden, Germany | Recruiting |
| Universitätsklinikum Düsseldorf | Düsseldorf, Germany | Recruiting |
| KEM Kliniken Essen-Mitte | Essen, Germany | Recruiting |
| Universitätsklinikum Essen | Essen, Germany | Recruiting |
| Universitätsmedizin Göttingen | Göttingen, Germany | Recruiting |
| University Hospital Hamburg | Hamburg, Germany | Recruiting |
| Klinikum Hanau GmbH | Hanau, Germany | Recruiting |
| ZAGO - Zentrum für ambulante gynäkologische Onkologie | Krefeld, Germany | Not Yet Recruiting |
| Universitätsmedizin Mainz | Mainz, Germany | Recruiting |
| Universitätsklinikum Mannheim | Manheim, Germany | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05903833